Perreault, S., Larouche, V., Tabori, U., Hawkin, C., Lippé, S., Ellezam, B., . . . Jabado, N. (2019). A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 19(1), p. 9. doi:10.1186/s12885-019-6442-2
Chicago ZitierstilPerreault, Sébastien, et al. "A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway: TRAM-01." BMC Cancer 19, no. 1 (2019): 9.
MLA ZitierstilPerreault, Sébastien, et al. "A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway: TRAM-01." BMC Cancer 19.1 (2019): 9.